Ocugen (NASDAQ: OCGN) is one of 29 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it weigh in compared to its competitors? We will compare Ocugen to related businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ocugen and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocugen 0 0 0 0 N/A
Ocugen Competitors 283 1009 1713 86 2.52

As a group, “Surgical appliances & supplies” companies have a potential upside of 7.47%. Given Ocugen’s competitors higher possible upside, analysts clearly believe Ocugen has less favorable growth aspects than its competitors.

Profitability

This table compares Ocugen and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocugen N/A -34.96% 18.40%
Ocugen Competitors -125.72% -66.48% -24.94%

Volatility & Risk

Ocugen has a beta of 3, indicating that its stock price is 200% more volatile than the S&P 500. Comparatively, Ocugen’s competitors have a beta of 1.13, indicating that their average stock price is 13% more volatile than the S&P 500.

Valuation and Earnings

This table compares Ocugen and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ocugen N/A -$8.64 million -0.05
Ocugen Competitors $1.39 billion $142.47 million 17.64

Ocugen’s competitors have higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

56.3% of shares of all “Surgical appliances & supplies” companies are owned by institutional investors. 19.7% of Ocugen shares are owned by company insiders. Comparatively, 8.2% of shares of all “Surgical appliances & supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ocugen Company Profile

Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.

Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.